Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMAVANSERIN vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist and antagonist, with no affinity for dopamine receptors, modulating glutamate and dopamine signaling in the cortex and striatum.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Treatment of hallucinations and delusions associated with Parkinson's disease psychosis (FDA-approved)
Management of mild to moderate pain,Reduction of fever
34 mg orally once daily.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is approximately 50 hours, allowing once-daily dosing; steady state reached in about 2 weeks.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily metabolized by CYP3A4 and CYP3A5, with minor contributions from CYP2J2 and CYP2D6. The major metabolite is N-desmethylpimavanserin, which is pharmacologically active.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily hepatic metabolism, with approximately 60% excreted in feces and 20% in urine as metabolites; less than 5% excreted as unchanged drug.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Approximately 95% bound to plasma proteins, primarily albumin.
10-25% bound to albumin at therapeutic concentrations.
Volume of distribution is approximately 400 L (about 4.7 L/kg), indicating extensive extravascular distribution.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral bioavailability is approximately 20% due to extensive first-pass metabolism.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No dose adjustment for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to increased exposure and risk of QT prolongation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients (<18 years). No dosing recommendation.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment; use caution due to potential increased sensitivity and risk of QT prolongation. Monitor renal function and electrolytes.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
No FDA boxed warning.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Risk of QT interval prolongation; avoid use in patients with known QT prolongation or with drugs that prolong QT interval.,Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).,May cause somnolence, orthostatic hypotension, and gastrointestinal effects.,Gradual dose titration recommended to minimize adverse effects.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Known hypersensitivity to pimavanserin or any of its components.,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased exposure and risk of QT prolongation.,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may reduce efficacy.
Hypersensitivity to acetaminophen or any component of the formulation
Avoid grapefruit and grapefruit juice due to potential for increased pimavanserin exposure and QT prolongation risk. No other significant food interactions reported.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Pimavanserin is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 8 times the maximum recommended human dose. However, because animal studies are not always predictive of human response, pimavanserin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester risks are unknown; second and third trimester risks are not characterized. Use caution.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
It is not known whether pimavanserin is excreted in human milk. The molecular weight (approx. 540 Da) suggests possible excretion. No data on M/P ratio. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No pharmacokinetic studies in pregnant women are available. Dose adjustments are not established. Use the lowest effective dose if treatment is deemed necessary during pregnancy.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Pimavanserin is a 5-HT2A inverse agonist approved for Parkinson's disease psychosis. It does not worsen motor symptoms due to lack of dopamine receptor affinity. QT prolongation risk is dose-dependent; monitor ECG at baseline and after dose changes. Avoid use in patients with dementia-related psychosis due to increased mortality risk. A 1-week washout prior to initiation is recommended if switching from other antipsychotics. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Avoid grapefruit juice as it may increase drug levels.,Report any irregular heartbeat, fainting, or dizziness.,Do not drive or operate heavy machinery until effect on coordination is known.,Take this medication with or without food exactly as prescribed.,Do not stop abruptly without consulting your doctor.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Pimavanserin, a serotonin 5-HT2A receptor inverse agonist, may reduce the therapeutic efficacy of apomorphine, a non-ergoline dopamine agonist used for Parkinson's disease. By antagonizing 5-HT2A receptors, pimavanserin could counteract the dopamine-mediated effects of apomorphine, potentially leading to worsened motor control and reduced clinical benefit. This interaction may result in increased Parkinsonian symptoms and decreased response to apomorphine rescue therapy."
"Pimavanserin, a serotonin 5-HT2A receptor inverse agonist, may antagonize the effects of levodopa by blocking 5-HT2A receptors on dopaminergic neurons, potentially reducing the therapeutic efficacy of levodopa in treating Parkinson's disease. This interaction can lead to worsening of motor symptoms and decreased clinical response to levodopa therapy."
"The therapeutic efficacy of Rotigotine can be decreased when used in combination with Pimavanserin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMAVANSERIN vs INJECTAPAP, answered by our medical review team.
PIMAVANSERIN is a Serotonin Inverse Agonist that works by Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist and antagonist, with no affinity for dopamine receptors, modulating glutamate and dopamine signaling in the cortex and striatum.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMAVANSERIN and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMAVANSERIN is: 34 mg orally once daily.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMAVANSERIN and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMAVANSERIN is classified as Category A/B. Pimavanserin is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm w. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.